Sponsored Research at Tufts CSDD

As part of its broad research agenda, the Tufts Center for the Study of Drug Development conducts Sponsored Research on a wide variety of topics identified by individual or multiple companies. Sponsored Research typically focuses on operational or R&D management issues, and may entail creation of a multi-company working group, survey creation, collection of company data, and publication of aggregate analyses. Individual participating companies may also receive customized reports, comparing their benchmarks against an industry mean.

Tufts CSDD brings broad expertise, creativity, and over 35 years of experience to its Sponsored Research program. Here are some examples of what we offer:

  • Primary and Secondary Research - including surveys, executive and opinion leader interviews, focus groups, and original and secondary data analyses.
  • Facilitated Roundtables and Management Meetings - including small and large group conference-style presentations and moderated discussions held onsite at the sponsor organization or at a neutral location (for example at Tufts CSDD’s own conference facility).
  • White Papers and Custom Management Reports - including the compilation of source information, and the review and analysis of significant R&D trends. Tufts CSDD will work closely with the sponsor organizations throughout the process. At the conclusion of the project, Tufts CSDD will prepare a summary report* that may be submitted for publication in a trade or peer-review journal, as well as customized reports for sponsoring organizations.

* Note that the Tufts Center for the Study of Drug Development publishes aggregate analyses only; individual companies, drugs, and proprietary data are never identified.

The following are examples of Sponsored Research recently conducted by Tufts CSDD: 

  • Benchmark study on capacity planning, economics, and forecasting
  • Market sizing, structure, and trends analysis
  • Clinical trial efficiency assessment: analysis of protocol complexity and amendments
  • Quantitative assessment of the impact of clinical outsourcing on development performance, quality, and cost
  • Assessment of various R&D strategies and management practices
  • Long-range projection on adoption of new practices, technologies, and innovations
  • Opportunities for improved R&D efficiency and effectiveness

Multi-Company Working Groups

Meeting industry’s goal of improved R&D efficiency often depends on the willingness of individual companies to share with their industry peers insights gleaned from experiences with different R&D operating models and strategies. Moreover, by sharing internal drug development metrics, timely and reliable industry-wide benchmarks can be generated, which can lead to operational changes and improved performance.

As an independent and neutral academic research group, Tufts CSDD is in a unique position to convene such a group of companies, collect and analyze proprietary data, solicit insights, and prepare objective reports. We call this our Multi-Company Working Group program, and it has led to the creation of many compelling analyses, invaluable benchmarks, and novel insights into the drug development process.


If you have any questions or would like addition information regarding Sponsored Research or Multi-Company Working Groups, please .(JavaScript must be enabled to view this email address).


Invitation to Join Working Group Pharmacovigilance Operations and Strategies

Pharmaceutical companies have invested heavily in the development and implementation of a variety of strategies and practices to improve pharmacovigilance operations. To date, however, little data exist that benchmark sponsor practices and their measurable impact.

Tufts CSDD invites pharmaceutical and biotechnology companies and CROs to participate in what is sure to be, an interesting, informative, and influential Working Group to gather these critical benchmark metrics. The aim of this study is to evaluate critical issues, concerns, and barriers associated with pharmacovigilance sourcing, costs, strategies, signal management, and benefit-risk management solutions. Areas of current concern within pharmacovigilance operations will be evaluated, including budget, regulatory harmonization, importance of partnerships, value in data quality, integration of patient centricity, and role of new technologies. A better approach to these pharmacovigilance challenges can lead to large-scale societal impact.

We look forward to speaking with you about this project in more detail. For more information, contact Ms. Josie Awatin, Research Analyst, Tufts CSDD, at .(JavaScript must be enabled to view this email address) or 617-636-6782.